BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Gaza humanitarian efforts reach key milestone as UNICEF vaccinates some 13,000 children - 2'Home Alone' actor Joe Pesci said 'no' to this stunt until he saw a 9-year-old girl do it, says director Chris Columbus
- 3Israeli police block Latin Patriarch from Palm Sunday mass in Jerusalem
- 4Picking Childcare Administrations for Your Loved ones
- 5Vote in favor of your #1 Kind of Cap
- EU-funded BioSupPack project turns brewery waste into bioplastics
- Oldest sequenced RNA reveals details about a mammoth’s final moments 40,000 years
- Reveal Less popular Authentic Realities You Didn't Learn in School
- Treasure trove found in Egyptian tomb solves ancient mystery
- 4 Excellent Remote Headphones of 2024
- Tatiana Schlossberg, a granddaughter of JFK, is dead at 35 after cancer diagnosis
- The best overlooked performances of 2025
- Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- Viable Correspondence: Building Solid Connections
